GlaxoSmithKline (GSK) Invests $18.6 Million in Amicus Therapeutics, Inc. (FOLD) to Expand Fabry Disease Drug Deal  
7/18/2012 7:44:35 AM

GlaxoSmithKline has made an additional $18.6 million investment in Amicus Therapeutics as part of an expansion to the firms’ collaboration on development of Amicus’ pharmacological chaperone migalastat HCL (AT1001) for the treatment of Fabry disease. The investment by GSK, at $6.3 per share of common stock, means the firm now owns 19.9% of Amicus. The latter will also receive a $3.5 million milestone cash payment from GSK relating to achievement of a clinical development milestone earlier this year.